Prostate Cancer in Men with Treated Advanced Heart Failure: Should we keep Screening?.
Prostate Cancer in Men with Treated Advanced Heart Failure: Should we keep Screening?.
- 2020
Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007
CONCLUSION: Our cohort represents the largest known cohort with heart failure treated by LVAD/HT and PCa. Our median age of 59 at PCa diagnosis is considerably younger than the national median of 66.1 Of the 4 individuals diagnosed with PCa, 3 had high grade disease. Given the favorable long-term survival of these patients post-LVAD/HT, age-appropriate treatment for PCa should be continued post-implantation. Copyright (c) 2019. Published by Elsevier Inc. METHODS: Men aged 18-90 with normal pre-transplant PSA who underwent LVAD/HT at MWHC from 2007-2018 were identified. Serum PSA, PCa diagnosis, and treatment were captured and analyzed. Survival was analyzed using Kaplan-Meier curves. OBJECTIVES: To evaluate the outcomes of men diagnosed with prostate cancer (PCa) following implanted treatments for advanced heart failure. Given the increasingly favorable 10-year life expectancy, MedStar Washington Hospital Center (MWHC) screens heart transplant (HT) candidates for PCa and other malignancies prior to intervention. RESULTS: Data was available for 34 patients. Median age was 53 [IQR=51-58]. Median follow-up was 77mo (95% CI=40-87mo). Six men had post-implant elevated PSA (5.3; SD=8.5) and 4 were diagnosed with PCa. Median age of PCa diagnosis was 59 [IQR=58.5-62). As of 2018, 31 of the 34 patients were living, and none died from PCa. Five-year survival was 96% in those without PCa and 100% in those with PCa (figure 2).
English
0090-4295
10.1016/j.urology.2019.11.022 [doi] S0090-4295(19)31047-7 [pii]
*Early Detection of Cancer
*Heart Failure/co [Complications]
*Heart Failure/su [Surgery]
*Heart Transplantation
*Heart-Assist Devices
*Prostatic Neoplasms/co [Complications]
*Prostatic Neoplasms/di [Diagnosis]
Adolescent
Adult
Aged
Aged, 80 and over
Cohort Studies
Humans
Male
Middle Aged
Young Adult
MedStar Georgetown University Hospital Residents
MedStar Heart & Vascular Institute
MedStar Washington Hospital Center
Urology
Journal Article
Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007
CONCLUSION: Our cohort represents the largest known cohort with heart failure treated by LVAD/HT and PCa. Our median age of 59 at PCa diagnosis is considerably younger than the national median of 66.1 Of the 4 individuals diagnosed with PCa, 3 had high grade disease. Given the favorable long-term survival of these patients post-LVAD/HT, age-appropriate treatment for PCa should be continued post-implantation. Copyright (c) 2019. Published by Elsevier Inc. METHODS: Men aged 18-90 with normal pre-transplant PSA who underwent LVAD/HT at MWHC from 2007-2018 were identified. Serum PSA, PCa diagnosis, and treatment were captured and analyzed. Survival was analyzed using Kaplan-Meier curves. OBJECTIVES: To evaluate the outcomes of men diagnosed with prostate cancer (PCa) following implanted treatments for advanced heart failure. Given the increasingly favorable 10-year life expectancy, MedStar Washington Hospital Center (MWHC) screens heart transplant (HT) candidates for PCa and other malignancies prior to intervention. RESULTS: Data was available for 34 patients. Median age was 53 [IQR=51-58]. Median follow-up was 77mo (95% CI=40-87mo). Six men had post-implant elevated PSA (5.3; SD=8.5) and 4 were diagnosed with PCa. Median age of PCa diagnosis was 59 [IQR=58.5-62). As of 2018, 31 of the 34 patients were living, and none died from PCa. Five-year survival was 96% in those without PCa and 100% in those with PCa (figure 2).
English
0090-4295
10.1016/j.urology.2019.11.022 [doi] S0090-4295(19)31047-7 [pii]
*Early Detection of Cancer
*Heart Failure/co [Complications]
*Heart Failure/su [Surgery]
*Heart Transplantation
*Heart-Assist Devices
*Prostatic Neoplasms/co [Complications]
*Prostatic Neoplasms/di [Diagnosis]
Adolescent
Adult
Aged
Aged, 80 and over
Cohort Studies
Humans
Male
Middle Aged
Young Adult
MedStar Georgetown University Hospital Residents
MedStar Heart & Vascular Institute
MedStar Washington Hospital Center
Urology
Journal Article